Genomic Health (GHDX) 26.81 $GHDX
Reimbursement for In Vitro Diagnostic (IVD) Tests
M2 - Wed Apr 16, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlwp6x/reimbursement_for) has announced the addition of the "Reimbursement for In Vitro Diagnostic (IVD) Tests" report to their offering. The report studied some recent products and their success at the critical task of clearing payor standards and found that those with clinical studies backing up their effectiveness did far better. The finding was made in its new research report on the topic, Reimbursement for IVD Tests. In the United States, the Centers for Medicare and Medicaid Services (CMS) determines and implements payment methodologies for specific types of healthcare services covered by Medicare and Medicaid. These federal plans, which combined cover almost 100 million persons, represent the largest health care plans in the nation by a wide margin and thus most other public and private health plans defer to CMS regarding coverage decisions. Decision-makers focus on cost-savings, according to analysis, and reward products that save the healthcare system money and prove results. This is not easy for IVD products, but some form of trial is the preferred way. While randomized controlled trials remain the preferred study design for establishing the causal effects of medical interventions on patient outcomes, other study designs can sometimes substitute for them, particularly in the evaluation of diagnostic products. Well-designed, non-randomized observational studies like patient cohort studies, case control studies, registries, and surveillance studies may all provide evidence that is sufficiently strong to inform payers making coverage and payment determinations. The report cites three examples of test products that obtained reimbursement status: - AlloMap Developed by privately held XDx Inc., is thus far the only non-invasive gene expression test that assists physicians in identifying the absence of heart transplant rejection. - Agendia's MammaPrint test for lymph node negative breast cancer patients is used to estimate a woman's recurrence risk for early-stage (Stage I or II) breast cancer, and can help patients and physicians make a more informed decision about whether to use chemotherapy to reduce recurrence risk. - OncotypeDX, developed by publicly traded Genomic Health and introduced in 2004, quantifies the likelihood of disease recurrence in women with early-stage ER positive breast cancer and assesses the likely benefit from certain types of chemotherapy. In all cases these products were able to demonstrate effectiveness in clinical studies and that they produced cost-savings over other test products or in reduction of treatment costs. Reimbursement for IVD Tests contains detailed case studies of successful products, a complete explanation of the reimbursement process, statistics and relevant codes. Key Topics Covered: Chapter One: Executive Summary Chapter Two: CMS And Private Insurance Reimbursement Chapter Three: Important Issues In IVD Reimbursement Chapter Four: Case Studies In Obtaining For more information visit http://www.researchandmarkets.com/research/ql...sement_for
The Global Market for Biomarkers: Concise Analysis of the $25 Billion Industry
M2 - Tue Apr 15, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7r264/the_global_market) has announced the addition of the "The Global Market for Biomarkers: Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers" report to their offering. The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year. Many biomarkers are now successfully marketed with several of them part of a routine diagnostic and treatment plan, with new products in the pipeline. Biomarkers are anatomic, physiologic, genetic, biochemical or molecular parameters. Biomarkers are detectable and measureable by a variety of methods including laboratory assays and medical imaging. Each biomarker is characteristic as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body's tissues, and can suggest a cardiovascular event when levels are high. The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report. The report says the majority of competitive participation for medical biomarkers is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market, including multiproduct companies such as Abbott and Roche, as well as small niche developers, such as 20/20 GeneSystems, CardioDx or MemoryDx. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction To The Medical Biomarkers Industry Chapter Three: Industry Trends Chapter Four: Biomarkers In Cancer Chapter Five: Biomarkers In Cardiovascular Disease And Blood Disorders Chapter Six: Biomarkers In Endocrine And Immune Disorders Chapter Seven: Biomarkers In Infectious Disease Chapter Eight: Biomarkers In Nervous System Disorders Chapter Nine: Market Summary Chapter Ten: Company Profiles - 20/20 GeneSystems - Abbott Laboratories - Affymetrix - Agendia - Alere - Beckman Coulter - Becton Dickinson - Biocartis SA - Biodesix - bioMerieux - BioReference Laboratory - bioTheranostics - CardioDX - Celera Alameda - Clarient - deCODE Genetics - DiaGenic - Genomic Health - Johnson & Johnson - Life Techologies - Memory Dx - Myriad Genetics - Nanostring Technologies - OPKO Health - Provista Dx - Qiagen - Roche - Seimens Healthcare - Tethys Bioscience - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/r7...bal_market
Clinical Laboratory Services Market 2013-2018: Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Apr 15, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98zpd/clinical) has announced the addition of the "Clinical Laboratory Services - Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles" report to their offering. The Clinical Laboratory Services estimates the market at $99.1 billion for 2013, up 1.3% from the estimated value in 2008 of $92.7 billion. Faced with daunting reimbursement cuts and other challenges, the world market for clinical laboratory services grew just over one percent in the past five year. The report notes that while there are a number of drivers for this market: aging populations, a growing incidence of chronic diseases, increasing emphasis on diagnosis and disease monitoring, and a growth in advanced testing technologies and practices. However, there are also a number of inhibitors to growth such as the growing emphasis to reduce health costs and uncertain economic conditions, and these are dampening growth. In the United States, the U.S. Congress ultimately has the responsibility to adjust the Medicare fee schedule according to economic factors, including controlling costs, monitoring utilization, and ensuring adequate delivery of health care services. The passing of the Patient Protection and Affordable Care Act generated a number of provisions on laboratory fee schedules, mostly in the direction of reductions. These reductions were effective starting 2011 and will continue to be adjusted through 2015. Medicare has slashed reimbursement amounts for many common tests such as Vitamin B12, triglycerides and glucose nearly six percent between 2009 and 2013. Some tests, such as total iron or aluminum tests have been cut 19% and 30% respectively during that period. Bio-Reference Laboratories, Quest, Lab Corp, Myriad, and Spectra are among the leaders in the industry. Quest Diagnostics and LabCorp have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. Smaller, independent laboratories may find it difficult to keep up with the fast changing industry largely due to limited financial abilities to invest in new technologies and testing services. Some laboratories, such as Bio-Reference Labs have found success in operating on a regional basis while companies such as Myriad Genetics and Genomic Health remain competitive by focusing on more specialized genetic-based testing. Key Topics Covered: 1. Executive Summary 2. Industry Overview 3. CLIA Laboratory Registration, Laboratories By Type 4. Leading Market Participants 5. Market Trends And Summary Companies Mentioned - Bio-Reference Laboratories - Clarient, Inc. - DaVita - Genomic Health - Genoptix, Inc. - Genzyme Corporation - Laboratory Corporation of America (LabCorp) - Quest Diagnostics, Inc. - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/d98zpd/clinical
Invitae's Multi-Gene Panels Can Provide Clinical Benefit to Patients Seeking Hereditary Cancer Risk Assessment
Business Wire - Mon Apr 14, 3:00PM CDT
Invitae Corporation, a genetic information company, today announced the publication of initial data from its research collaboration with Stanford University in the Journal of Clinical Oncology, published online on April 14. The study demonstrates that multi-gene hereditary cancer panels can offer comparable performance to traditional BRCA1/2 genetic testing and can provide additional clinical benefit to doctors and patients seeking cancer risk assessment.
11.8% Return Seen to Date on SmarTrend Genomic Health Call (GHDX)
Comtex SmarTrend(R) - Mon Apr 14, 9:25AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 3 months, Genomic Health has returned 11.82% as of today's recent price of $26.63.
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Genomic Health Down 13.6% Since SmarTrend Downtrend Call (GHDX)
Comtex SmarTrend(R) - Thu Apr 03, 10:02AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 2 months, Genomic Health has returned 13.61% as of today's recent price of $26.09.
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Kevin Cook - ZACKS - Thu Apr 03, 3:09AM CDT
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Genomic Health Unveils Oncotype DX Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 5:15PM CDT
Genomic Health presents results from multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference.
Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX® in Europe
PR Newswire - Wed Mar 19, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9th European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.
Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX(R) in Europe
PR Newswire Europe - Wed Mar 19, 3:01AM CDT
-- Data Presented at 9th European Breast Cancer (EBCC-9) Symposium Highlights Comprehensive Body of Clinical Evidence for Oncotype DX
Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating
M2 - Tue Mar 18, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brn9sx/global_imaging) has announced the addition of the "Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating" report to their offering. The use of imaging biomarkers in the field of drug discovery has increased considerably over the past few years. The increase in the demand for imaging biomarkers is primarily because of their ability to be used in target discovery and validation, identification of disease mechanisms, toxicity profiling, and proof-of-concept studies. The Global Imaging Biomarkers market has been witnessing an increase in the number of strategic alliances being formed among organizations. Mergers and acquisitions help organizations grow rapidly, expand their business processes, and gain more market share. The introduction of innovative technologies by small and mid-sized companies is prompting major pharmaceutical and biotechnology companies to form strategic alliances with these smaller companies to identify various imaging biomarkers. The increase in strategic alliances is resulting in an increase in the application base for imaging biomarkers in drug discovery and diagnosis domains. For instance, in 2012, Genomic Health Inc. and OncoMed Pharmaceuticals announced a strategic alliance for Biomarker Research and Discovery using the Next-generation Sequencing process. Further, the report states that one of the main challenges hindering the growth of this market is the presence of poor regulatory and reimbursements systems. The current regulatory and reimbursement systems present in various countries are not well-suited for imaging biomarker-based diagnostics. The development of novel and useful imaging biomarkers is also an expensive and time-consuming process. The key vendors dominating this market space are: - Abbott Laboratories - Agilent Technologies Inc. - Affymetrix Inc. - Bio-Rad Laboratories Inc. - F. Hoffmann La Roche Ltd. - Gen-Probe Inc. - Siemens Healthcare. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Buying Criteria 09. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Trends and their Impact 15. Vendor Landscape 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/br...al_imaging
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018
M2 - Tue Mar 11, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9dp8rj/cancertumor) has announced the addition of the "Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018" report to their offering. The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment. The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Tumor Profiling Technology Landscape 4 Tumor Profiling Research Portfolio 5 Value Chain Analysis 6 Market Landscape Analysis 7 Technology Adoption And Development Potential, By Geography 8 Technology Investment Analysis 9 Competitive Landscape Analysis 10 Patent Analysis 11 Analyst Insights And Recommendations 12 Company Profiles Companies Mentioned: - Agendia Nv - Biotheranostics - Boreal Genomics, Inc - Caris Life Sciences - Genomic Health, Inc - Illumina, Inc - Life Technologies Corporation - Nanostring Technologies - Neogenomics Laboratories - Oncopath Laboratory - Oxford Gene Technology Ltd - Precision Therapeutics, Inc - Proteome Sciences Plc - Rational Therapeutics - Ribomed Biotechnologies For more information visit http://www.researchandmarkets.com/research/9d...ancertumor
Diagnostics Marketing Association Names Genomic Health its 2013 Marketer of the Year
PRWeb - Thu Mar 06, 8:11AM CST
The Diagnostics Marketing Association (DxMA) announced today its 2013 Marketer of the Year: Genomic Health. This award recognizes diagnostic industry innovation by marketers in highlighting their company and/or products and will be presented during the annual DxMA Global Marketing Summit to be held in San Francisco, CA on April 16-17, 2014.
Downtrend Call Working As Genomic Health Stock Falls 13.7% (GHDX)
Comtex SmarTrend(R) - Mon Mar 03, 10:59AM CST
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 1 month, Genomic Health has returned 13.68% as of today's recent price of $26.07.
Reimbursement for In Vitro Diagnostic (IVD) Tests
M2 - Wed Apr 16, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlwp6x/reimbursement_for) has announced the addition of the "Reimbursement for In Vitro Diagnostic (IVD) Tests" report to their offering. The report studied some recent products and their success at the critical task of clearing payor standards and found that those with clinical studies backing up their effectiveness did far better. The finding was made in its new research report on the topic, Reimbursement for IVD Tests. In the United States, the Centers for Medicare and Medicaid Services (CMS) determines and implements payment methodologies for specific types of healthcare services covered by Medicare and Medicaid. These federal plans, which combined cover almost 100 million persons, represent the largest health care plans in the nation by a wide margin and thus most other public and private health plans defer to CMS regarding coverage decisions. Decision-makers focus on cost-savings, according to analysis, and reward products that save the healthcare system money and prove results. This is not easy for IVD products, but some form of trial is the preferred way. While randomized controlled trials remain the preferred study design for establishing the causal effects of medical interventions on patient outcomes, other study designs can sometimes substitute for them, particularly in the evaluation of diagnostic products. Well-designed, non-randomized observational studies like patient cohort studies, case control studies, registries, and surveillance studies may all provide evidence that is sufficiently strong to inform payers making coverage and payment determinations. The report cites three examples of test products that obtained reimbursement status: - AlloMap Developed by privately held XDx Inc., is thus far the only non-invasive gene expression test that assists physicians in identifying the absence of heart transplant rejection. - Agendia's MammaPrint test for lymph node negative breast cancer patients is used to estimate a woman's recurrence risk for early-stage (Stage I or II) breast cancer, and can help patients and physicians make a more informed decision about whether to use chemotherapy to reduce recurrence risk. - OncotypeDX, developed by publicly traded Genomic Health and introduced in 2004, quantifies the likelihood of disease recurrence in women with early-stage ER positive breast cancer and assesses the likely benefit from certain types of chemotherapy. In all cases these products were able to demonstrate effectiveness in clinical studies and that they produced cost-savings over other test products or in reduction of treatment costs. Reimbursement for IVD Tests contains detailed case studies of successful products, a complete explanation of the reimbursement process, statistics and relevant codes. Key Topics Covered: Chapter One: Executive Summary Chapter Two: CMS And Private Insurance Reimbursement Chapter Three: Important Issues In IVD Reimbursement Chapter Four: Case Studies In Obtaining For more information visit http://www.researchandmarkets.com/research/ql...sement_for
The Global Market for Biomarkers: Concise Analysis of the $25 Billion Industry
M2 - Tue Apr 15, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7r264/the_global_market) has announced the addition of the "The Global Market for Biomarkers: Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers" report to their offering. The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year. Many biomarkers are now successfully marketed with several of them part of a routine diagnostic and treatment plan, with new products in the pipeline. Biomarkers are anatomic, physiologic, genetic, biochemical or molecular parameters. Biomarkers are detectable and measureable by a variety of methods including laboratory assays and medical imaging. Each biomarker is characteristic as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body's tissues, and can suggest a cardiovascular event when levels are high. The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report. The report says the majority of competitive participation for medical biomarkers is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market, including multiproduct companies such as Abbott and Roche, as well as small niche developers, such as 20/20 GeneSystems, CardioDx or MemoryDx. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction To The Medical Biomarkers Industry Chapter Three: Industry Trends Chapter Four: Biomarkers In Cancer Chapter Five: Biomarkers In Cardiovascular Disease And Blood Disorders Chapter Six: Biomarkers In Endocrine And Immune Disorders Chapter Seven: Biomarkers In Infectious Disease Chapter Eight: Biomarkers In Nervous System Disorders Chapter Nine: Market Summary Chapter Ten: Company Profiles - 20/20 GeneSystems - Abbott Laboratories - Affymetrix - Agendia - Alere - Beckman Coulter - Becton Dickinson - Biocartis SA - Biodesix - bioMerieux - BioReference Laboratory - bioTheranostics - CardioDX - Celera Alameda - Clarient - deCODE Genetics - DiaGenic - Genomic Health - Johnson & Johnson - Life Techologies - Memory Dx - Myriad Genetics - Nanostring Technologies - OPKO Health - Provista Dx - Qiagen - Roche - Seimens Healthcare - Tethys Bioscience - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/r7...bal_market
Clinical Laboratory Services Market 2013-2018: Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Apr 15, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98zpd/clinical) has announced the addition of the "Clinical Laboratory Services - Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles" report to their offering. The Clinical Laboratory Services estimates the market at $99.1 billion for 2013, up 1.3% from the estimated value in 2008 of $92.7 billion. Faced with daunting reimbursement cuts and other challenges, the world market for clinical laboratory services grew just over one percent in the past five year. The report notes that while there are a number of drivers for this market: aging populations, a growing incidence of chronic diseases, increasing emphasis on diagnosis and disease monitoring, and a growth in advanced testing technologies and practices. However, there are also a number of inhibitors to growth such as the growing emphasis to reduce health costs and uncertain economic conditions, and these are dampening growth. In the United States, the U.S. Congress ultimately has the responsibility to adjust the Medicare fee schedule according to economic factors, including controlling costs, monitoring utilization, and ensuring adequate delivery of health care services. The passing of the Patient Protection and Affordable Care Act generated a number of provisions on laboratory fee schedules, mostly in the direction of reductions. These reductions were effective starting 2011 and will continue to be adjusted through 2015. Medicare has slashed reimbursement amounts for many common tests such as Vitamin B12, triglycerides and glucose nearly six percent between 2009 and 2013. Some tests, such as total iron or aluminum tests have been cut 19% and 30% respectively during that period. Bio-Reference Laboratories, Quest, Lab Corp, Myriad, and Spectra are among the leaders in the industry. Quest Diagnostics and LabCorp have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. Smaller, independent laboratories may find it difficult to keep up with the fast changing industry largely due to limited financial abilities to invest in new technologies and testing services. Some laboratories, such as Bio-Reference Labs have found success in operating on a regional basis while companies such as Myriad Genetics and Genomic Health remain competitive by focusing on more specialized genetic-based testing. Key Topics Covered: 1. Executive Summary 2. Industry Overview 3. CLIA Laboratory Registration, Laboratories By Type 4. Leading Market Participants 5. Market Trends And Summary Companies Mentioned - Bio-Reference Laboratories - Clarient, Inc. - DaVita - Genomic Health - Genoptix, Inc. - Genzyme Corporation - Laboratory Corporation of America (LabCorp) - Quest Diagnostics, Inc. - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/d98zpd/clinical
Invitae's Multi-Gene Panels Can Provide Clinical Benefit to Patients Seeking Hereditary Cancer Risk Assessment
Business Wire - Mon Apr 14, 3:00PM CDT
Invitae Corporation, a genetic information company, today announced the publication of initial data from its research collaboration with Stanford University in the Journal of Clinical Oncology, published online on April 14. The study demonstrates that multi-gene hereditary cancer panels can offer comparable performance to traditional BRCA1/2 genetic testing and can provide additional clinical benefit to doctors and patients seeking cancer risk assessment.
11.8% Return Seen to Date on SmarTrend Genomic Health Call (GHDX)
Comtex SmarTrend(R) - Mon Apr 14, 9:25AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 3 months, Genomic Health has returned 11.82% as of today's recent price of $26.63.
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Genomic Health Down 13.6% Since SmarTrend Downtrend Call (GHDX)
Comtex SmarTrend(R) - Thu Apr 03, 10:02AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 2 months, Genomic Health has returned 13.61% as of today's recent price of $26.09.
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Kevin Cook - ZACKS - Thu Apr 03, 3:09AM CDT
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Genomic Health Unveils Oncotype DX Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 5:15PM CDT
Genomic Health presents results from multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference.
Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX® in Europe
PR Newswire - Wed Mar 19, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9th European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.
Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX(R) in Europe
PR Newswire Europe - Wed Mar 19, 3:01AM CDT
-- Data Presented at 9th European Breast Cancer (EBCC-9) Symposium Highlights Comprehensive Body of Clinical Evidence for Oncotype DX
Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating
M2 - Tue Mar 18, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brn9sx/global_imaging) has announced the addition of the "Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating" report to their offering. The use of imaging biomarkers in the field of drug discovery has increased considerably over the past few years. The increase in the demand for imaging biomarkers is primarily because of their ability to be used in target discovery and validation, identification of disease mechanisms, toxicity profiling, and proof-of-concept studies. The Global Imaging Biomarkers market has been witnessing an increase in the number of strategic alliances being formed among organizations. Mergers and acquisitions help organizations grow rapidly, expand their business processes, and gain more market share. The introduction of innovative technologies by small and mid-sized companies is prompting major pharmaceutical and biotechnology companies to form strategic alliances with these smaller companies to identify various imaging biomarkers. The increase in strategic alliances is resulting in an increase in the application base for imaging biomarkers in drug discovery and diagnosis domains. For instance, in 2012, Genomic Health Inc. and OncoMed Pharmaceuticals announced a strategic alliance for Biomarker Research and Discovery using the Next-generation Sequencing process. Further, the report states that one of the main challenges hindering the growth of this market is the presence of poor regulatory and reimbursements systems. The current regulatory and reimbursement systems present in various countries are not well-suited for imaging biomarker-based diagnostics. The development of novel and useful imaging biomarkers is also an expensive and time-consuming process. The key vendors dominating this market space are: - Abbott Laboratories - Agilent Technologies Inc. - Affymetrix Inc. - Bio-Rad Laboratories Inc. - F. Hoffmann La Roche Ltd. - Gen-Probe Inc. - Siemens Healthcare. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Buying Criteria 09. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Trends and their Impact 15. Vendor Landscape 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/br...al_imaging
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018
M2 - Tue Mar 11, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9dp8rj/cancertumor) has announced the addition of the "Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018" report to their offering. The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment. The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Tumor Profiling Technology Landscape 4 Tumor Profiling Research Portfolio 5 Value Chain Analysis 6 Market Landscape Analysis 7 Technology Adoption And Development Potential, By Geography 8 Technology Investment Analysis 9 Competitive Landscape Analysis 10 Patent Analysis 11 Analyst Insights And Recommendations 12 Company Profiles Companies Mentioned: - Agendia Nv - Biotheranostics - Boreal Genomics, Inc - Caris Life Sciences - Genomic Health, Inc - Illumina, Inc - Life Technologies Corporation - Nanostring Technologies - Neogenomics Laboratories - Oncopath Laboratory - Oxford Gene Technology Ltd - Precision Therapeutics, Inc - Proteome Sciences Plc - Rational Therapeutics - Ribomed Biotechnologies For more information visit http://www.researchandmarkets.com/research/9d...ancertumor
Diagnostics Marketing Association Names Genomic Health its 2013 Marketer of the Year
PRWeb - Thu Mar 06, 8:11AM CST
The Diagnostics Marketing Association (DxMA) announced today its 2013 Marketer of the Year: Genomic Health. This award recognizes diagnostic industry innovation by marketers in highlighting their company and/or products and will be presented during the annual DxMA Global Marketing Summit to be held in San Francisco, CA on April 16-17, 2014.
Downtrend Call Working As Genomic Health Stock Falls 13.7% (GHDX)
Comtex SmarTrend(R) - Mon Mar 03, 10:59AM CST
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 1 month, Genomic Health has returned 13.68% as of today's recent price of $26.07.
